Misty Shields

Hematology | Oncology

535 Barnhill Dr Ste 210
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

High-Quality Care in Small Cell Lung Cancer: Highlighting Therapeutic Advancements and Integration of Early Palliative Care.

High-Quality Care in Small Cell Lung Cancer: Highlighting Therapeutic Advancements and Integration of Early Palliative Care.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 09, 2026

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.

Journal: Investigational new drugs

Published: April 06, 2026

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Prognostic Significance and Biomarker Identification by Progression Patterns in Patients With Small Cell Lung Cancer After Immune Checkpoint Inhibitors.

Prognostic Significance and Biomarker Identification by Progression Patterns in Patients With Small Cell Lung Cancer After Immune Checkpoint Inhibitors.

Journal: Clinical lung cancer

Published: November 30, 2025

Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series.

Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series.

Journal: Clinical lung cancer

Published: July 18, 2025

Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review.

Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review.

Journal: Clinical lung cancer

Published: June 30, 2025

ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.

ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.

Journal: Molecular cancer therapeutics

Published: June 24, 2025

SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.

SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 11, 2025

Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.

Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.

Journal: Cancer

Published: April 28, 2025

CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC).

CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2025

CLO25-059: Exploring Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Squamous Cell Carcinoma (LSCC) in North America.

CLO25-059: Exploring Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Squamous Cell Carcinoma (LSCC) in North America.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

BPI25-018: Impact of Early Palliative Care on Outcomes in Small Cell Lung Cancer.

BPI25-018: Impact of Early Palliative Care on Outcomes in Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Showing 1-12 of 31

Last Updated: 09/26/2026